ArticleThe Laryngoscope2026
Unique Features of Nasal Airway and Airflow Improvement Post-Dupilumab: A Computational Cohort Study.
Article in The Laryngoscope, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
objectiveDupilumab is a monoclonal antibody approved for treatment of chronic rhinosinusitis (CRS) with nasal polyps, yet literature is sparse regarding its precise effect on nasal airway patency and airflow patterns. This study applied Computational Fluid Dynamics (CFD) modeling to examine the relationship between the changes in nasal structures and aerodynamics and the changes in symptoms after dupilumab treatment.
methodsTwelve patients enrolled, completed the Sinonasal Outcomes Score (SNOT-22), as well as CT scans pre and 3 or more months post-dupilumab treatment. Patient-specific CFD models were constructed, and Lund-Mackay (LM) scores were calculated.
resultsNasal airway cross-sectional area (CSA) and airflow rate (AFR) in the middle and superior but not inferior meatuses significantly increased posttreatment (all p < 0.05). These increases correlated with SNOT-22 scores (CSA: r = 0.49, AFR: r = 0.41, p < 0.05), as well as with one question in SNOT-22, decreased sense of smell/taste (CSA: r = 0.32-0.54, AFR: r = 0.29-0.53, p < 0.05), which may explain previously reported rapid improvement in olfaction post-dupilumab. Surprisingly, nasal resistance did not significantly decrease posttreatment (p = 0.12) nor significantly correlate with symptom scores. LM scores significantly improved post-dupilumab (14.4 ± 6.3 to 9.8 ± 4.6; p < 0.05), with moderate residual inflammation. LM significantly correlated with SNOT-22 scores (r = 0.46, p < 0.05), but not with smell/taste complaints.
conclusionThe impact of dupilumab on nasal airway patency and airflow is not uniform. It is more pronounced in the middle and superior, but not inferior meatus. These unique regional changes significantly correlate with and potentially drive the improvement in patient symptoms. LEVEL OF EVIDENCE: 3:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.